Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(1 site)
China
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian